Neurovascular Devices Market to grow at a CAGR of 8.22% during 2026 to 2035; Driven by Rising Prevalence of Neurovascular Disorders and Advancements in Minimally Invasive Treatment Technologies

Market Research Future (MRFR) has published the updated report on the global Neurovascular Devices Market, valuing the market at USD 5.17 billion in 2025 and projecting it to grow from USD 5.56 billion in 2026, reaching USD 10.48 billion by 2035 at a compound annual growth rate (CAGR) of 8.22% during the forecast period 2026--2035.

Medicare’s new reimbursement policy for carotid stenting, an estimated USD 2.8 billion in cumulative venture investment in next-generation stroke treatment devices from 2022 to 2025, and a definitive technology shift away from legacy open-surgery approaches toward catheter-based endovascular neurology devices guided by advanced flat-panel CT and robotic navigation platforms are reshaping the market.

Market Overview

With stroke remaining the second-leading cause of death and a top-three cause of disability worldwide, neurovascular devices have become a strategic need for healthcare systems worldwide. The combination of mechanical thrombectomy guideline expansion, flow-diverter innovation and AI-guided catheter systems is fundamentally changing the treatment of intracranial aneurysms and large-vessel occlusions and creating a fertile growth environment for endovascular device makers, robotic navigation platforms and stroke center infrastructure providers around the world.

North America accounts for approximately 47% of the global market share, driven by standardized mechanical thrombectomy methods in over 1,800 certified stroke centers. Europe represents around 26% of the worldwide market, and device refresh cycles are driven by updates for compliance with EU MDR regulations. The Asia-Pacific region is anticipated to be the fastest-growing market with a projected CAGR of 9.28% through 2035, owing to the massive investment in stroke-ready hospital infrastructure by China and India.

Key Market Trends & Growth Drivers

• Mechanical Thrombectomy Guideline Expansion: The American Heart Association’s 2024 revised guidelines doubled the qualifying treatment window for mechanical thrombectomy, from 6 hours to 24 hours after symptom onset, for some patients with large-vessel blockage, roughly tripling the number of procedures that can be performed in the US. In the first full year of implementation, hospital systems that invested in stroke therapy equipment saw a 22% year-over-year increase in thrombectomy case numbers. This extension immediately benefits manufacturers of neurothrombectomy devices, and it sets a clinical standard that is expected to be adopted by Asian and European stroke associations by 2027.


• Reimbursement Broadening Across Key Markets: In early 2024, CMS finalized Medicare coverage of carotid artery stenting for more clinical situations, eliminating prior authorization hurdles that previously hampered the use of cerebrovascular intervention tools in community hospitals. The policy change is estimated to lead to around USD 320 million in extra spending on procedures by 2028. Likewise, Japan’s National Health Insurance broadened coverage for endovascular neurology devices to treat intracranial stenosis, prompting purchases at more than 400 stroke facilities.


• Robotic Navigation and AI-Guided Systems: Siemens Healthineers’ Corindus subsidiary and Stereotaxis have installed robotic catheter navigation systems in over 120 neuro-interventional rooms worldwide, saving fluoroscopy time by 38% on average and operator radiation dose by 52%. These systems improve procedural accuracy for intracranial stent system and aspiration catheter deployment in tortuous vascular anatomy. Surveys of hospital capital expenditures suggest that 35% of US comprehensive stroke centers plan to acquire robotic systems by 2028.


• Aging Population and Rising Global Stroke Incidence: WHO estimates global stroke incidence to rise 25% between 2025 and 2035, driven by population aging in OECD nations and metabolic-risk escalation in low- and middle-income countries. Each percentage-point increase in stroke incidence translates to roughly 150,000 additional potential candidates for endovascular neurology devices annually, sustaining baseline demand for the Neurovascular Devices Market irrespective of technology cycles.


• Flow-Diverter and Next-Gen Aneurysm Coiling Equipment Innovation: Bioresorbable intracranial stent systems like MicroVention’s FRED X2 and Stryker’s Surpass Evolve 2.0 have demonstrated vascular remodeling at 18 months in clinical studies, addressing the long-term foreign-body issues of permanent metallic implants. By 2028, commercialization of these platforms could change the aneurysm coiling equipment industry and increase therapeutic candidacy.

Market Segmentation Insights

By Product: The aneurysm coiling and embolization devices category accounted for the highest share of the Neurovascular Devices Market in 2025, with 34.8% of the sales. The market share of this sector was driven by physician familiarity, as well as abundant clinical evidence supporting aneurysm coiling equipment. The neurothrombectomy devices market is growing at a CAGR of 9.14% through 2035, owing to new AHA/ASA guidelines supporting mechanical thrombectomy within a 24-hour timeframe. Cerebral balloon angioplasty and stenting systems contributed ~USD 1.12 billion in 2025, driven by the increased uptake of intracranial stent systems for symptomatic stenosis.

By Target Disease: In 2025, ischemic stroke treatments were the largest illness segment of the Neurovascular Devices Market due to the sheer epidemiological burden of almost 13.7 million new strokes occurring worldwide each year. The cerebral aneurysm interventions are expected to register a CAGR of 8.86% due to increasing utilization of flow diverters in both elective and emergency situations. Rounding out the key target categories are intracranial atherosclerotic disease and arteriovenous malformation.

By End User: Hospitals accounted for 63% of the Neurovascular Devices Market share in 2025, due to the concentration of neuro-interventional suites within tertiary care settings. Ambulatory surgical centers are the fastest-growing end-user channel with a CAGR of 9.37% as payers approve outpatient cerebrovascular intervention tools for lower acuity procedures. Research institutions and military medical facilities demand generate USD 0.19 billion from specialty clinics.

By Technology: Stent retrievers and large-bore aspiration catheters are vying for the first-line position for acute ischemic stroke, with Stryker’s Trevo NXT and Penumbra’s Lightning systems each reporting TICI 2b/3 rates of more than 85 percent. Flow diverters are the fastest-expanding technology platform, with next-generation devices such as MicroVention's FRED X2 demonstrating complete vessel remodeling in 18 months. Embolic Coils are evolving with softer fill properties and 360-degree deployment vision.

Regional Landscape

North America -- Technology Adoption Leader

North America holds a significant share of the Neurovascular Devices Market, accounting for nearly 47% of the global market. Growth in the region is driven by over 1,800 Joint Commission-certified stroke facilities, active payer coverage of mechanical thrombectomy, and Medicare’s expanded carotid stenting reimbursement policy. The US dominates the region with 82% of the regional contribution, with the NIH investing more than USD 410 million for stroke-related neuroscience research alone in fiscal 2024. Canadian provincial stroke-network standardization also plays an important role with a CAGR of 7.68%. Mexico is rising as a growth market. Procurement of neurovascular devices by IMSS public hospitals is forecast to reach USD 0.09 billion in 2025.

Europe -- Emerging Market Dynamics

Europe contributes roughly 26% of the global market, driven by upgrades to comply with the EU MDR, stroke network optimization, and standardized regulatory processes. Germany dominates the regional adoption, accounting for 28% of the regional share, supported by DRG payment codes that completely cover thrombectomy treatments. The United Kingdom is the next largest market with a CAGR of 7.85%, as the NHS has committed to providing mechanical thrombectomy in every integrated stroke delivery network by 2027, requiring a large procurement of stroke treatment devices across 24 designated thrombectomy hubs. The big markets are rounded out by France, Italy and Spain, with the Nordic countries taking the lead in high per capita healthcare spending. Key businesses like Medtronic and Stryker are driving innovation, and competition is heating up with a rising base of specialized neurovascular pure-plays.

Asia-Pacific -- Rapid Growth and Innovation

Asia-Pacific is the fastest-growing region in the Neurovascular Devices Market with an estimated CAGR of 9.28% till 2035. Infrastructure build-out, national stroke programs and increasing stroke awareness efforts, notably in China and India, are driving growth. China has a 38% share of the regional market, with the 14th Five-Year Plan committing funds for stroke infrastructure at county-level hospitals and global device companies such as Medtronic and MicroPort pursuing localization initiatives. India follows with a 10.15% CAGR as the National Programme for Prevention and Control of Non-Communicable Diseases is creating 150 new stroke-ready units by 2027 with INR 1,200 crore funding. Japan and South Korea are at the forefront of NHI expanded indications and cerebrovascular reimbursement reform, with Japan projected to generate USD 0.21 billion in 2025.

Middle East and Africa -- Untapped Market Potential

The Middle East and Africa region has a smaller but growing share of the global market, driven by the development of tertiary-care hubs and rising demand for devices used in stroke treatment. Saudi Arabia is the largest contributor to the region’s share, with Vision 2030 investing over USD 65 billion in healthcare infrastructure, including dedicated neuroscience institutes in Riyadh and Jeddah that are purchasing endovascular neurology devices at scale. The UAE’s stance for medical tourism is supported by JCI-accredited stroke facilities, supporting a CAGR of 8.63%. South Africa’s Netcare and Life Healthcare private-sector investment and Egypt’s public-hospital enhancements in neurology are beginning to increase access to cerebrovascular intervention techniques to broader populations.

Competitive Landscape

The neurovascular devices market is moderately concentrated, and it is estimated that the top five firms possess a combined share of 62–68%. Key Players in the Neurovascular Devices and Equipment Market: Medtronic plc, Stryker Corporation, Penumbra, Inc., MicroVention (Terumo), Johnson & Johnson (Cerenovus), Balt Group, Phenox GmbH, MicroPort Scientific, Acandis GmbH, Wallaby Medical. Recent important developments are:

• In January 2025, Medtronic plc signed an exclusive US distribution agreement with Contego Medical for its Neuroguard IEP integrated stent-balloon-filter technology, boosting its portfolio of cerebrovascular intervention tools.


• Q’Apel Medical received the Armadillo CE mark for the SelectFlex 7F neurovascular access system in January 2025, expanding its European market access for its catheter platforms.


• Stryker Corporation launched the Trevo NXT thrombectomy device in 2024, reporting TICI 2b/3 recanalization rates of greater than 85% and further solidifying its leadership position in thrombectomy.


• R&D of Penumbra Inc.’s Lightning aspiration system with AI-guided catheter in 2024, offering an aspiration-first strategy with embedded intelligent clot detection.


• MicroVention progressed its FRED X2 flow diverter through clinical trials in 2024, exhibiting complete vessel remodeling at 18 months, and moving toward commercialization in 2028.


• Johnson & Johnson (Cerenovus) expanded the reach of its EMBOTRAP III stent retriever and Cascade micro-platform in stroke centers across the Asia-Pacific through its global distribution network in 2024.

Future Outlook

Further advancements in AI-powered stroke triage and decision-support software, greater ambulatory surgical center delivery of elective cerebrovascular procedures, and deeper penetration into emerging markets across Asia-Pacific, the Middle East, and Africa will also transform the Neurovascular Devices Market by 2035. Organizations focused on AI-infused procedural guidance with real-time catheter navigation optimization, next-generation flow diverters and biodegradable stents eliminating long-term foreign-body issues, and value-based reimbursement with bundling of outcomes are positioned for outsized growth.

Critical growth opportunities identified in the MRFR report include the deployment of AI-powered stroke triage systems that cut door-to-puncture times by 20–30 minutes, development of ambulatory surgical center expansion strategies for elective aneurysm coiling and carotid stenting, and customized neurovascular device expansion in high-growth emerging markets where government-funded stroke infrastructure build-outs guarantee baseline demand for endovascular neurology devices and intracranial stent systems.